EUVIMEDEUVIMED entdecken
VergleichsstudieSystematische ÜbersichtUmbrella ReviewOpen Access · CC BY 4.0

Comparison of GLP‐1 Receptor Agonists, SGLT‐2 Inhibitors, and DPP‐4 Inhibitors as an Add‐On Drug to Insulin Combined With Oral Hypoglycemic Drugs: Umbrella Review

Sanbao Chai iD, Yapin Niu iD, Fengqi Liu iD, Shanshan Wu iD, Zhirong Yang iD, Feng Sun iD

Journal of Diabetes Research · 2024

DOI: 10.1155/2024/8145388 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Journal of Diabetes Research, 2024. Verfasst von Sanbao Chai und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology and Metabolism Peking University International Hospital, Beijing 102206, China. Hauptthemen laut MEDLINE: Sodium-Glucose Transporter 2 Inhibitors, Dipeptidyl-Peptidase IV Inhibitors, Diabetes Mellitus, Type 2, Hypoglycemic Agents. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The objective was to evaluate the efficacy of the combination of Glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs), dipeptidyl peptidase‐4 inhibitors (DPP‐4i), and sodium‐glucose cotransporter 2 inhibitor (SGLT‐2i) in the treatment of Type 2 diabetes with poor efficacy of basic insulin and metformin/sulfonylurea by umbrella review. Materials and Methods: Forming the data of publication of each database through 13 September 2022, PubMed, EMBASE, and Cochrane Library were surveyed.

Results

A total of seven meta‐analyses were included in the umbrella review. The combination of GLP‐1 RA (WMD −3.41 [−5.61, −1.21], p = 0.002), SGLT‐2i (WMD −5.34 [−9.56, −1.13], p = 0.013), and DPP‐4i (WMD −5.56 [−7.39, −3.73], p ≤ 0.001) can significantly reduce HbA1c levels, respectively. The combination of GLP‐1 RA (WMD −1.55 [−2.92, −0.18], p = 0.027), SGLT‐2i (WMD −2.96 [−6.68, 0.77], p = 0.12), and DPP‐4i (WMD −2.05 [−2.82, −1.28], p ≤ 0.001) can significantly reduce fasting plasma glucose (FPG) levels, respectively. The combination of GLP‐1 RA (WMD −3.24 [−5.14, −1.34], p < 0.001) can significantly reduce body weight of Type 2 diabetes mellitus (T2DM). The dose of basic insulin in diabetes patients after combined use of GLP‐1 RA (WMD −2.74 [−4.26, −1.22], p ≤ 0.001) was significantly reduced. The combination use of GLP‐1 RAs (OR 1.28 [1.05, 1.56], p = 0.017) increases the risk of hypoglycemia.

Conclusions

The combination of GLP‐1 RAs, DPP‐4i, and SGLT‐2i can effectively lower HbA1c and FPG in T2DM patients who have poor therapeutic effects on basic insulin combined with metformin/sulfonylureas, respectively. Compared to placebo, GLP‐1 RAs can significantly reduce body weight and basic insulin dosage, while DPP‐4i and SGLT‐2i have a lower risk of hypoglycemia. Trial Registration: CRD42023410345 .

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Sodium-Glucose Transporter 2 InhibitorsDipeptidyl-Peptidase IV InhibitorsDiabetes Mellitus, Type 2Hypoglycemic AgentsInsulinDrug Therapy, CombinationGlucagon-Like Peptide-1 Receptor AgonistsHumansBlood GlucoseGlycated HemoglobinTreatment OutcomeAdministration, Oral

Stichwörter der Autor:innen

DPP-4GLP-1SGLT-2Type 2 diabetesbasic insulinumbrella review

Substanzen

Sodium-Glucose Transporter 2 InhibitorsDipeptidyl-Peptidase IV InhibitorsHypoglycemic AgentsInsulinBlood GlucoseGlycated HemoglobinGlucagon-Like Peptide-1 Receptor Agonists

Autor:innen und Institutionen

  • Department of Endocrinology and Metabolism Peking University International Hospital, Beijing 102206, China.
  • Department of Epidemiology and Biostatistics Peking University School of Public Health, Beijing 100083, China.
  • National Clinical Research Center of Digestive Diseases Capital Medical University Affiliated Beijing Friendship Hospital, Beijing 100050, China.
  • Shenzhen Institute of Advanced Technology Chinese Academy of Sciences, Shenzhen 518055, China.
  • Key Laboratory of Epidemiology of Major Disease (Peking University) Ministry of Education, Beijing 100191, China.

ORCID-Profile: Sanbao Chai, Yapin Niu, Fengqi Liu, Shanshan Wu, Zhirong Yang, Feng Sun

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Chai, S., Niu, Y., Liu, F., Wu, S., Yang, Z., & Sun, F. (2024). Comparison of GLP‐1 Receptor Agonists, SGLT‐2 Inhibitors, and DPP‐4 Inhibitors as an Add‐On Drug to Insulin Combined With Oral Hypoglycemic Drugs: Umbrella Review. Journal of Diabetes Research. https://doi.org/10.1155/2024/8145388

Vancouver

Chai S, Niu Y, Liu F, Wu S, Yang Z, Sun F. Comparison of GLP‐1 Receptor Agonists, SGLT‐2 Inhibitors, and DPP‐4 Inhibitors as an Add‐On Drug to Insulin Combined With Oral Hypoglycemic Drugs: Umbrella Review. Journal of Diabetes Research. 2024. doi:10.1155/2024/8145388

BibTeX
@article{Chai2024,
  author = {Chai, Sanbao and Niu, Yapin and Liu, Fengqi and Wu, Shanshan and Yang, Zhirong and Sun, Feng},
  title = {Comparison of GLP‐1 Receptor Agonists, SGLT‐2 Inhibitors, and DPP‐4 Inhibitors as an Add‐On Drug to Insulin Combined With Oral Hypoglycemic Drugs: Umbrella Review},
  journal = {Journal of Diabetes Research},
  year = {2024},
  doi = {10.1155/2024/8145388}
}
Kostenlos starten →